Literature DB >> 8818122

An empirical note on willingness to pay and starting-point bias.

N O Stålhammar1.   

Abstract

One of the most serious sources of potential bias when using the contingent valuation (CV) method to assess willingness to pay (WTP) is implied-value cues, i.e., different types of starting-point bias. The possible existence of starting-point bias is serious, since it may be interpreted to mean that the responders' preferences are very unstable. While the empirical evidence from environmental economics on starting-point bias is mixed, an earlier study in health economics did not find any clear evidence of starting-point bias. However, in the study presented here, a clear presence of starting-point bias was found. In a Swedish survey of how and when patients take antisecretory drugs, the patients were asked about their willingness to pay for a medication that can be taken in relation to meals compared with one that must be taken at least one hour before meals and has the additional disadvantage that it interacts with contraceptive pills. Among the 105 respondents, 82 were willing to pay a sum in addition to the normal patient fee in order to obtain the drug that could be taken during meals. The 82 patients thereafter participated in the bidding game that could start at a low bid (SEK 20) or a high bid (SEK 1,000). On average, the patients were willing to pay an additional SEK 138 (1 SEK = 0.13 U.S. dollar, April 1995) to obtain the superior drug. However, the average WTP among the 42 patients who started at the low bid was 70 SEK, which should be compared to an average of 289 SEK among the 40 patients who initially were offered the high bid.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8818122     DOI: 10.1177/0272989X9601600308

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  9 in total

1.  Assessing willingness to pay for cancer prevention.

Authors:  Michael A Milligan; Alok K Bohara; José A Pagán
Journal:  Int J Health Care Finance Econ       Date:  2010-07-16

Review 2.  A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?

Authors:  Tracey H Sach; Richard D Smith; David K Whynes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach.

Authors:  P Davey; D Grainger; J MacMillan; N Rajan; M Aristides; M Dobson
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

4.  Measurement of consumer preference for treatments used to induce labour: a willingness-to-pay approach.

Authors:  Susan J. Taylor; Carol L. Armour
Journal:  Health Expect       Date:  2000-09       Impact factor: 3.377

5.  Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.

Authors:  George Dranitsaris; Julia Elia-Pacitti; Wayne Cottrell
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

6.  The equivalence of numbers: the social value of avoiding health decline: an experimental Web-based study.

Authors:  David L B Schwappach
Journal:  BMC Med Inform Decis Mak       Date:  2002-03-05       Impact factor: 2.796

7.  Influenced from the start: anchoring bias in time trade-off valuations.

Authors:  Liv Ariane Augestad; Knut Stavem; Ivar Sønbø Kristiansen; Carl Haakon Samuelsen; Kim Rand-Hendriksen
Journal:  Qual Life Res       Date:  2016-03-26       Impact factor: 4.147

8.  Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis.

Authors:  Leslie S Wilson; Traci M Blonquist; Fangxin Hong; Barbara Halpenny; Seth Wolpin; Peter Chang; Christopher P Filson; Viraj A Master; Martin G Sanda; Gary W Chien; Randy A Jones; Tracey L Krupski; Donna L Berry
Journal:  BMC Med Inform Decis Mak       Date:  2019-01-09       Impact factor: 2.796

9.  The Value of Statistical Life and the Economics of Landmine Clearance in Developing Countries.

Authors:  John Gibson; Sandra Barns; Michael Cameron; Steven Lim; Frank Scrimgeour; John Tressler
Journal:  World Dev       Date:  2007-01-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.